Outpatient Care Pathway for Patients Treated Intra-arterially for Primary Liver Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

206

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions
Hepato Cellular Carcinoma (HCC)
Interventions
OTHER

Ambulatory care

Patients with Hepato cellular carcinoma (HCC) treated by chemo-embolization (CEH) or radioembolization (REH) are managed on an outpatient basis: hospitalization in an outpatient unit, followed by systematic telephone and on-demand nursing follow-up for 48 hours for REH and 72 hours for CEH. A dedicated re-hospitalization circuit has also been set up in the event of complications.

OTHER

Conventional inpatient care

Patients with Hepato cellular carcinoma (HCC) treated by chemo-embolization (CEH) or radioembolization (REH) are managed on an inpatient basis: conventional hospitalization.

Trial Locations (16)

25030

University hospital of Besançon, Besançon

29609

University hospital of Brest, Brest

33607

Univesity hospital of Bordeaux, Pessac

34090

University hospital of Montpellier, Montpellier

38700

University hospital of Grenoble-Alpes, La Tronche

44093

Nantes, Nantes

49933

University hospital of Angers, Angers

63003

University hospital of Clermont-Ferrand, Clermont-Ferrand

75013

Hospital of Pitié-Salpétrière (AP-HP), Paris

75014

Hospital of Cochin (AP-HP), Paris

80054

University hospital of Amiens, Amiens

85925

Hospital of Vendée, La Roche-sur-Yon

92110

Hospital of Beaujon (AP-HP), Clichy

94805

Institut Gustave Roussy (IGR), Villejuif

Unknown

Hospital of Avicennes (AP-HP), Bobigny

06202

University hospital of Nice, Nice

All Listed Sponsors
collaborator

Université Paris Cité

OTHER

lead

University Hospital, Angers

OTHER_GOV

NCT06990659 - Outpatient Care Pathway for Patients Treated Intra-arterially for Primary Liver Cancer | Biotech Hunter | Biotech Hunter